MENU
+Compare
IMTX
Stock ticker: NASDAQ
AS OF
Nov 25, 04:59 PM (EDT)
Price
$10.98
Change
+$0.38 (+3.58%)
Capitalization
1.33B

IMTX Immatics NV Forecast, Technical & Fundamental Analysis

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more

IMTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for IMTX with price predictions
Nov 24, 2025

Momentum Indicator for IMTX turns positive, indicating new upward trend

IMTX saw its Momentum Indicator move above the 0 level on November 18, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IMTX just turned positive on November 21, 2025. Looking at past instances where IMTX's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMTX advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

IMTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IMTX entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.779) is normal, around the industry mean (27.722). P/E Ratio (27.608) is within average values for comparable stocks, (51.664). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.908). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (13.550) is also within normal values, averaging (322.739).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
IMTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMTX is expected to report earnings to fall 11.07% to -37 cents per share on March 25

Immatics NV IMTX Stock Earnings Reports
Q4'25
Est.
$-0.37
Q3'25
Missed
by $0.04
Q2'25
Missed
by $0.28
Q1'25
Missed
by $0.07
Q4'24
Beat
by $0.74
The last earnings report on November 17 showed earnings per share of -41 cents, missing the estimate of -38 cents. With 528.40K shares outstanding, the current market capitalization sits at 1.33B.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Paul-Ehrlich-Strasse 15
Phone
+49 707153970
Employees
343
Web
https://www.immatics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EEMCX14.650.19
+1.31%
Columbia Emerging Markets C
RDWFX13.620.14
+1.04%
American Funds Dvlpg Wld Gr&Inc R5
TSFCX12.33N/A
N/A
Touchstone Small Cap C
TTMIX161.84N/A
N/A
T. Rowe Price Comm & Tech I
HLRRX9.68-0.01
-0.10%
LDR Real Estate Value Opportunity Instl

IMTX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with IDYA. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMTX
1D Price
Change %
IMTX100%
+3.92%
IDYA - IMTX
54%
Loosely correlated
+2.00%
VYGR - IMTX
52%
Loosely correlated
-1.91%
CGON - IMTX
51%
Loosely correlated
+2.66%
SYRE - IMTX
50%
Loosely correlated
+11.25%
OCUL - IMTX
50%
Loosely correlated
-1.18%
More